JPH10501682A - 細胞毒性t細胞エピトープ - Google Patents
細胞毒性t細胞エピトープInfo
- Publication number
- JPH10501682A JPH10501682A JP7523739A JP52373995A JPH10501682A JP H10501682 A JPH10501682 A JP H10501682A JP 7523739 A JP7523739 A JP 7523739A JP 52373995 A JP52373995 A JP 52373995A JP H10501682 A JPH10501682 A JP H10501682A
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- barr virus
- cell
- cytotoxic
- epstein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title description 48
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims abstract description 48
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 26
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 20
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 1
- 230000035772 mutation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 31
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 241000700605 Viruses Species 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 239000011651 chromium Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 101150089665 EBNA4 gene Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 206010046865 Vaccinia virus infection Diseases 0.000 description 4
- -1 carrier Substances 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 208000007089 vaccinia Diseases 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001440741 CHER virus Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101150113929 EBNA2 gene Proteins 0.000 description 1
- 101150034762 EBNA3 gene Proteins 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241001200922 Gagata Species 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000003478 cholangiolocellular carcinoma Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 230000002185 fusiogenic effect Effects 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.QAKWRLQTL、RYSIFFDY、HLAAQGMAY、YPLHE QHGM、SVRDRLARL、AVLLHEESM、VSFIEFVGW、F RKAQIQGL、PYLFWLAAI、TVFYNIPPMPL、PGDQL PGFSDGRACPV、VEITPYKPTW、及びそれらの変異型からなる 群から選択されるエピトープであることを特徴とする細胞毒性エプステイン-バ ーウィルスT細胞エピトープ。 2.前記エピトープが、QAKWRLQTLであることを特徴とする請求項1記 載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 3.前記エピトープが、RYSIFFDYであることを特徴とする請求項1記載 の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 4.前記エピトープが、HLAAQGMAYであることを特徴とする請求項1記 載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 5.前記エピトープが、YPLHEQHGMであることを特徴とする請求項1記 載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 6.前記エピトープが、SVRDRLARLであることを特徴とする請求項1記 載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 7.前記エピトープが、AVLLHEESMであることを特徴とする請求項1記 載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 8.前記エピトープが、VSFIEFVGWであることを特徴とする請求項1記 載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 9.前記エピトープが、FRKAQIQGLであることを特徴とする請求項1記 載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 10.前記エピトープが、PYLFWLAAIであることを特徴とする請求項1 記載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 11.前記エピトープが、TVFYNIPPMPLであることを特徴とする請求 項1記載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 12.前記エピトープが、PGDQLPGFSDGRACPVであることを特徴 とする請求項1記載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 13.前記エピトープが、VEITPYKPTWであることを特徴とする請求項 1記載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 14.前記エピトープが、YPLHKOHGM、YRLHEQHGM、及びYP LHEQRGMからなる群から選択されるYPLHEQHGMの変異型であるこ とを特徴とする請求項1記載の細胞毒性エプステイン-バーウィルスT細胞エピ トープ。 15.前記エピトープが、TVLLHEESM及びTALLHEESMからなる 群から選択されるAVLLHEESMの変異型であることを特徴とする請求項1 記載の細胞毒性エプステイン-バーウィルスT細胞エピトープ。 16.請求項1から15のいずれかに記載の細胞毒性エプステイン-バーウィル スT細胞エピトープに、少なくとも1つの製薬的に許容されるアジュバント、キ ャリヤ、希釈剤、または賦型剤を混合してなることを特徴とする患者にCTLを 誘発させるための組成物。 17.請求項1から15のいずれかに記載の細胞毒性エプステイン-バーウィル スT細胞エピトープに、少なくとも1つの製薬的に許容されるアジュバント、キ ャリヤ、希釈剤、または賦型剤を混合することからなることを特徴とする患者に CTLを誘発させるための組成物の製法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU4465 | 1994-03-16 | ||
AUPM4465A AUPM446594A0 (en) | 1994-03-16 | 1994-03-16 | Cytotoxic t-cell epitopes identified within epstein-barr virus |
PCT/AU1995/000140 WO1995024925A1 (en) | 1994-03-16 | 1995-03-16 | Cytotoxic t-cell epitopes |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10501682A true JPH10501682A (ja) | 1998-02-17 |
Family
ID=3779080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7523739A Pending JPH10501682A (ja) | 1994-03-16 | 1995-03-16 | 細胞毒性t細胞エピトープ |
Country Status (7)
Country | Link |
---|---|
US (1) | US5869453A (ja) |
JP (1) | JPH10501682A (ja) |
AU (1) | AUPM446594A0 (ja) |
CA (2) | CA2185540A1 (ja) |
GB (1) | GB2301591B (ja) |
NZ (1) | NZ282348A (ja) |
WO (2) | WO1995024926A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO007396A0 (en) * | 1996-05-24 | 1996-06-20 | Csl Limited | Ebv ctl epitopes |
US6699477B2 (en) | 1996-05-24 | 2004-03-02 | The Council Of The Queensland Institute Of Medical Research | EBV CTL epitopes |
SE9603468D0 (sv) * | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
SE9603463D0 (sv) * | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
AUPO784197A0 (en) | 1997-07-10 | 1997-08-07 | Csl Limited | Treatment of nasopharyngeal carcinoma |
US6866239B2 (en) * | 2000-02-18 | 2005-03-15 | Metal Forms Corporation | Concrete form assembly |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
WO2003105665A2 (en) * | 2002-06-14 | 2003-12-24 | Mayo Foundation For Medical Education And Research | Epstein-barr virus-specific immunization |
ATE516045T1 (de) | 2003-01-24 | 2011-07-15 | Univ Massachusetts Medical | Identifikation von vaccinia-virus-dominanten t- zell-epitopen |
US8067535B2 (en) | 2003-01-24 | 2011-11-29 | The University Of Massachusetts | Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes |
JP6081483B2 (ja) | 2011-12-12 | 2017-02-15 | セル・メディカ・リミテッド | T細胞を増殖させるプロセス |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
DK3591047T3 (da) | 2012-02-09 | 2022-10-24 | Baylor College Medicine | Peptidblandinger til generering af multivirale CTL¿er med bred specificitet |
WO2014059489A1 (en) | 2012-10-19 | 2014-04-24 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
CN105555756B (zh) | 2013-06-28 | 2018-12-07 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
BR112017013574A2 (pt) * | 2014-12-23 | 2018-03-06 | Verdon Daniel | conjugados de aminoácido e peptídeo e usos dos mesmos |
JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
JP7161404B2 (ja) | 2016-02-26 | 2022-10-26 | オークランド ユニサービシーズ リミティド | アミノ酸及びペプチド接合体及び接合方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU220295B (hu) * | 1991-07-25 | 2001-11-28 | Idec Pharmaceuticals Corp. | Antigénkészítmények és ezek alkalmazása citotoxikus T-limfocita reakciók indukálására |
CA2077277A1 (en) * | 1991-09-09 | 1993-03-10 | John J. Donnelly | Cellular immunity vaccines from bacterial toxin-antigen conjugates |
WO1993019092A1 (fr) * | 1992-03-19 | 1993-09-30 | Centre National De La Recherche Scientifique | Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr |
JP3755890B2 (ja) * | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
EP0605432B1 (en) * | 1992-06-25 | 2001-12-05 | City Of Hope | Induction of cytolytic t-lymphocytes with cytomegalovirus polypeptides |
US5683695A (en) * | 1993-02-10 | 1997-11-04 | United Biomedical, Inc. | Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains |
IL113484A0 (en) * | 1994-04-28 | 1995-07-31 | Immunex Corp | Viral proteins pharmaceutical compositions containing them their preparation and use |
-
1994
- 1994-03-16 AU AUPM4465A patent/AUPM446594A0/en not_active Abandoned
-
1995
- 1995-03-16 WO PCT/AU1995/000141 patent/WO1995024926A1/en active Application Filing
- 1995-03-16 CA CA002185540A patent/CA2185540A1/en not_active Abandoned
- 1995-03-16 US US08/704,655 patent/US5869453A/en not_active Expired - Lifetime
- 1995-03-16 GB GB9619232A patent/GB2301591B/en not_active Expired - Fee Related
- 1995-03-16 JP JP7523739A patent/JPH10501682A/ja active Pending
- 1995-03-16 NZ NZ282348A patent/NZ282348A/en unknown
- 1995-03-16 CA CA002185541A patent/CA2185541C/en not_active Expired - Fee Related
- 1995-03-16 WO PCT/AU1995/000140 patent/WO1995024925A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AUPM446594A0 (en) | 1994-04-14 |
US5869453A (en) | 1999-02-09 |
CA2185541C (en) | 2007-09-18 |
GB2301591B (en) | 1998-05-27 |
GB2301591A (en) | 1996-12-11 |
WO1995024925A1 (en) | 1995-09-21 |
NZ282348A (en) | 1998-05-27 |
CA2185541A1 (en) | 1995-09-21 |
CA2185540A1 (en) | 1995-09-21 |
GB9619232D0 (en) | 1996-10-23 |
WO1995024926A1 (en) | 1995-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10501682A (ja) | 細胞毒性t細胞エピトープ | |
JP4574166B2 (ja) | 新規なヒトサイトメガロウイルス(hcmv)細胞傷害性t細胞エピトープ、ポリエピトープ、それを含む組成物、ならびにその診断、予防および治療上の使用 | |
US7160685B2 (en) | Diagnostic reagents for human cytomegalovirus and methods of use | |
CN100526331C (zh) | 来自ebv的ctl表位 | |
US5019384A (en) | Immunonodulating compositions and their use | |
AU5103293A (en) | Immortalized cells and uses therefor | |
CA2173138A1 (en) | Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide | |
JP2004123708A (ja) | ヒトT細胞応答誘発組成物に用いるためのヒトp53タンパク質のペプチドおよびヒトp53タンパク質特異的細胞毒性Tリンパ球 | |
JP2569185B2 (ja) | 抗hiv応答を喚起する合成抗原 | |
WO1988000057A1 (en) | Immunomodulating compositions and their use | |
AU675204B2 (en) | Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides | |
WO1991004051A1 (en) | Peptides including ctl epitopes of hiv proteins and use thereof | |
JPH05500653A (ja) | リウマチ様関節炎の処置法 | |
US20110142911A1 (en) | HIV epitopes and pharmaceutical composition containing same | |
US5346989A (en) | Peptides for use in induction of T cell activation against HIV-1 | |
JP3757220B2 (ja) | エプスタイン−バーウィルスからの免疫反応性ペプチド | |
JP2010029217A (ja) | Hiv特異的ctlを誘導し得るペプチド及び該ペプチドを含む抗aids予防・治療剤 | |
Sundaram et al. | Protective Efficacy of Multiepitope Human Leukocyte Antigen–A* 0201 Restricted Cytotoxic T-Lymphocyte Peptide Construct Against Challenge With Human T-Cell Lymphotropic Virus Type 1 Tax Recombinant Vaccinia Virus | |
US5158884A (en) | Immunodominant acetylcholine receptor peptides useful for T-helper cell sensitization | |
WO2004111080A1 (en) | Epitopes of the cytomegalovirus pp65 protein | |
AU724248B2 (en) | Cytotoxic T-Cell epitopes | |
AU756081B2 (en) | CTL epitopes from EBV | |
CA1301064C (en) | Immunomodulating compositions and their use | |
TWI329647B (en) | Vaccines | |
CN116322736A (zh) | 诱导针对SARS-CoV-2的免疫的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040601 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040831 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050208 |